Please assess the completion status of the following clinical trial:

Trial Title: Adjunctive Cilostazol Versus High Maintenance-dose ClopidogrEL in Acute Myocardial Infarction (AMI) Patients According to CYP2C19 Polymorphism

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. The patient must be at least 18 years of age.~2. clinical symptoms compatible with acute myocardial ischemia within 12 h before admission with a subsequently documented increase in cardiac markers.~3. Measured pre-discharge platelet reactivity in case of normalized CK-MB value after coronary stenting.~Exclusion Criteria:~1. A history of active bleeding and bleeding diatheses.~2. Oral anticoagulation therapy with coumadin.~3. Contraindication to antiplatelet therapy.~4. LV ejection fraction \< 30% or NYHA 3/4.~5. Leukocyte count \< 3,000/mm3 and/or platelet count \< 100,000/mm3.~6. AST or ALT ≥ 3 times upper normal.~7. Serum creatinine level ≥ 2.5 mg/dl.~8. Stroke within 3 months.~9. Non-cardiac disease with a life expectancy \< 1 year.~10. Inability to follow the protocol.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- triple group (Type: ACTIVE_COMPARATOR): Additive cilostazol to dual antiplatelet therapy (triple antiplatelet therapy) in patients with acute myocardial infarction (AMI).~Received cilostazol 100 mg twice daily in addition to aspirin 100 mg and clopidogrel 75 mg once daily.
- high maintenance dose group (Type: ACTIVE_COMPARATOR): High maintenance dose dual antiplatelet therapy in patients with acute myocardial infarction (AMI).~Received clopidogrel 150 mg/day with aspirin 100 mg once daily.

Based on this trial design, predict the completion outcome and termination type (if applicable).